Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration

Jeffrey S. Heier, David M. Brown, Victor Chong et al. · Ophthalmology · 2012 · 2.5K citations

Medicine, Ophthalmology, Vision Science +16

Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR Study

David M. Brown, Mark Michels, Peter K. Kaiser et al. · Ophthalmology · 2008 · 1.3K citations

Medicine, Ophthalmology, Surgery +15

Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy

F. L. Ferris, Shai Fine, Leslie Hyman · Archives of Ophthalmology · 1984 · 1.1K citations

Medicine, Ophthalmology, Vision Science +16

Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration

Ursula Schmidt‐Erfurth, Peter K. Kaiser, Jean‐François Korobelnik et al. · Ophthalmology · 2013 · 811 citations

Medicine, Ophthalmology, Pharmacotherapy +14

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials

The Lancet · 2022 · 686 citations · Full text

Medicine, Ophthalmology, Vision Science +11